People: Targacept Inc (TRGT.OQ)
TRGT.OQ on NASDAQ Stock Exchange Global Select Market
5.05USD
1:04pm EDT
5.05USD
1:04pm EDT
Price Change (% chg)
$-0.03 (-0.59%)
$-0.03 (-0.59%)
Prev Close
$5.08
$5.08
Open
$5.05
$5.05
Day's High
$5.07
$5.07
Day's Low
$5.02
$5.02
Volume
9,839
9,839
Avg. Vol
59,325
59,325
52-wk High
$5.77
$5.77
52-wk Low
$3.86
$3.86
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Mark Skaletsky |
64 | 2002 | Independent Chairman of the Board |
Stephen Hill |
54 | 2012 | President, Chief Executive Officer, Director |
Alan Musso |
50 | 2010 | CFO, Senior Vice President - Finance and Administration, Treasurer, Assistant Secretary |
Peter Zorn |
41 | 2010 | Senior Vice President - Legal Affairs, General Counsel, Secretary |
Merouane Bencherif |
57 | 2010 | Senior Vice President - Preclinical Research |
Mauri Hodges |
54 | 2010 | Vice President - Finance and Corporate Systems, Controller |
Karen Hicks |
60 | 2010 | Vice President - Human Resources |
David Hosford |
2013 | Vice President - Clinical Development and Regulatory Affairs | |
Charles Blixt |
62 | 2000 | Independent Director |
Julia Brown |
66 | 2007 | Independent Director |
Errol De Souza |
59 | 2004 | Independent Director |
Alan Dunton |
59 | 2006 | Independent Director |
John Richard |
54 | 2002 | Independent Director |
Biographies
| Name | Description |
|---|---|
Mark Skaletsky |
Mr. Mark B. Skaletsky, Ph.D., is Independent Chairman of the Board of Targacept Inc. Since May 2008, Mr. Skaletsky has been the chairman and chief executive officer of Fenway Pharmaceuticals, Inc., a biotechnology company. From March 2001 to March 2008, he served as the chairman and chief executive officer of Trine Pharmaceuticals, Inc., a biotechnology company. Mr. Skaletsky is currently a member of the board of directors of each of the publicly-traded companies Alkermes, Inc. and ImmunoGen, Inc. and, within the past five years, he served on the board of directors of the publicly-traded company AMAG Pharmaceuticals, Inc. Mr. Skaletsky is also a member of the board of trustees of Bentley University. |
Stephen Hill |
Dr. Stephen A. Hill, M.D. has been appointed as President, Chief Executive Officer, Director of Targacept, Inc., effective December 1, 2012. Dr. Hill brings over 20 years of industry experience to the role, having served previously as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc. and ArQule, Inc. At Solvay, he led an organization of over 1,200 employees until its acquisition by Abbott Laboratories in 2010. Dr. Hill's responsibilities included the direct management of the U.S. commercial organization and administrative support of U.S.-based clinical development, project management, quality, regulatory affairs and new business development. At ArQule, he led a transition from a fee-for-service discovery chemistry model to an enterprise with a proprietary clinical-stage pipeline. Prior to ArQule, Dr. Hill held several leadership positions with F. Hoffmann-La Roche Ltd., including Global Head of Clinical Development. Dr. Hill currently serves as non-executive Chairman of the Board of Directors of each of Novelos Therapeutics, Inc. and Audeo Oncology Inc. In addition, Dr. Hill served for seven years with the National Health Service in the United Kingdom in General and Orthopedic Surgery. He is a Fellow of the Royal College of Surgeons of England and received his Bachelor of Medicine and Bachelor of Surgery from St. Catherine's College at Oxford University. |
Alan Musso |
Mr. Alan A. Musso, CPA., C.M.A. is Senior Vice President - Finance and Administration, Chief Financial Officer, Treasurer and Assistant Secretary of Targacept, Inc. He has been Company's Senior Vice President, Finance and Administration since March 2010, Company's Chief Financial Officer and Treasurer since February 2002 and Company's Assistant Secretary since June 2007. He was Company's Vice President from February 2002 to March 2010 and Company's Secretary from February 2002 to June 2007. |
Peter Zorn |
Mr. Peter A. Zorn, Esq., is Senior Vice President - Legal Affairs, General Counsel and Secretary of Targacept, Inc. He has been Company's Senior Vice President, Legal Affairs since March 2010, Company's General Counsel since January 2006 and Company's Secretary since June 2007. He was Company's Vice President, Legal Affairs from January 2006 to March 2010, Company's Corporate Counsel from May 2003 to January 2006 and Company's Assistant Secretary from May 2003 to June 2007. Mr. Zorn resides in Bedford, Massachusetts. |
Merouane Bencherif |
Dr. Merouane Bencherif, M.D., Ph.D., serves as Senior Vice President - Preclinical Research of Targacept Inc. He was Company's Vice President, Preclinical Research from August 2002 to March 2010 and Company's Vice President, Biological Sciences from August 2000 to August 2002. |
Mauri Hodges |
Ms. Mauri K. Hodges, CPA., C.C.P, is Vice President - Finance and Corporate Systems, Controller of Targacept, Inc. She has been Company's Vice President, Finance and Corporate Systems since March 2010 and Company's Controller since November 2000. She was Company's Senior Director, Finance from February 2002 to March 2010. |
Karen Hicks |
Ms. Karen A. Hicks serves as Vice President - Human Resources of Targacept, Inc., since March 2010. She was Company's Senior Director, Human Resources from January 2007 to March 2010 and Company's Director, Human Resources from September 2002 to January 2007. |
David Hosford |
Dr. David A. Hosford, M.D., Ph.D., has been appointed as Vice President - Clinical Development and Regulatory Affairs of Targacept Inc., effective June 28, 2013. |
Charles Blixt |
Mr. Charles A. Blixt is an Independent Director of Targacept, Inc., since August 2000. From October 2007 to December 2010, Mr. Blixt was a senior advisor to Jones Day, a law firm. From September 2006 to April 2007, he served as the interim general counsel of Krispy Kreme Doughnuts, Inc., a branded specialty retailer. From August 2004 to August 2006, he was executive vice president, general counsel and assistant secretary of Reynolds American Inc. From June 1999 to August 2006, he held positions of increasing responsibility with R.J. Reynolds Tobacco Holdings, Inc. and, from January 1998 to August 2006, he served as executive vice president and general counsel of R.J. Reynolds Tobacco Company. Mr. Blixt is a member of the board of directors of the publicly-traded company Krispy Kreme Doughnuts, Inc. Within the past five years, he served as a member of the board of directors of the publicly-traded company Swedish Match AB. |
Julia Brown |
Ms. Julia R. Brown is an Independent Director of Targacept, Inc., since November 2007. From January 2000 until her retirement in September 2008, Ms. Brown was affiliated with Amylin Pharmaceuticals, Inc., a biopharmaceutical company, serving as executive vice president until July 2003 and then as an adviser to the chief executive officer. She is chairman of the board of trustees of the University of California San Diego Foundation. In 2010, Ms. Brown received an award for “Distinguished Contribution to the Life Science Industry” from CONNECT, an organization that fosters innovation and the formation of new technology companies in southern California and for which she serves as a director. Within the past five years, she served on the board of directors of each of the publicly-traded companies Labopharm, Inc. (acquired by Palatin Labs Inc.) and Tanox, Inc. (acquired by Genentech, Inc.). |
Errol De Souza |
Dr. Errol B. De Souza, Ph.D. is an Independent Director of Targacept, Inc., since January 2004. Since March 2010, Dr. De Souza has been president and chief executive officer of Biodel Inc., a specialty pharmaceutical company. From April 2009 to March 2010, Dr. De Souza was a pharmaceutical and biotechnology consultant. From April 2003 to March 2009, he served as president and chief executive officer of Archemix Corporation, a privately held biopharmaceutical company. Dr. De Souza currently serves as chairman of the steering board for GlaxoSmithKline’s Immunology Inflammation Center of Excellence for Drug Discovery, as a member of the investment committee for Royalty Pharma and as a member of the board of directors of each of the publicly-traded companies Biodel Inc. and Bionomics Ltd. Within the past five years, he served on the board of directors of each of the publicly-traded companies IDEXX Laboratories, Inc. and Palatin Technologies, Inc. |
Alan Dunton |
Dr. Alan W. Dunton, M.D., is an Independent Director of Targacept, Inc., since October 2006. Since April 2006, he has been president of Danerius, LLC, a consulting company. From January 2007 to March 2009, Dr. Dunton served as president and chief executive officer of Panacos Pharmaceuticals Inc. and he served as a managing director of Panacos from March 2009 to January 2011. Dr. Dunton is a member of the board of directors of each of the publicly-traded companies EpiCept Corporation, Oragenics, Inc. and Palatin Technologies, Inc. Within the past five years, he served on the board of directors of each of the publicly-traded companies Adams Respiratory Therapeutics, Inc. (acquired by Reckitt Benckiser Group plc) and MediciNova, Inc. and the formerly publicly-traded company Panacos Pharmaceuticals, Inc. |
John Richard |
Mr. John P. Richard is an Independent Director of Targacept, Inc., since November 2002. Since June 2005, Mr. Richard has been a managing director of Georgia Venture Partners, LLC, a venture capital firm that focuses on the biotechnology industry. He has also served as senior business advisor to Agennix AG, a biotechnology company, since April 1999 and as a non-executive director of Phase4 Ventures Limited, a private equity fund, since March 2011. From 2008 until March 2011, Mr. Richard served as a venture partner of Nomura Phase4 Ventures LP. In addition, Mr. Richard currently serves and from time to time during at least the past five years has served as a consultant to portfolio companies of Georgia Venture Partners, as well as to Nomura Phase4 Ventures (or an affiliated entity) and certain of its portfolio companies. Within the past five years, Mr. Richard served as a member of the board of directors of the formerly publicly-traded company Altus Pharmaceuticals Inc. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Mark Skaletsky |
-- |
Stephen Hill |
-- |
Alan Musso |
1,145,620 |
Peter Zorn |
1,120,620 |
Merouane Bencherif |
438,644 |
Mauri Hodges |
-- |
Karen Hicks |
-- |
David Hosford |
-- |
Charles Blixt |
-- |
Julia Brown |
-- |
Errol De Souza |
-- |
Alan Dunton |
-- |
John Richard |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Mark Skaletsky |
0 | 0 |
Stephen Hill |
0 | 0 |
Alan Musso |
169,231 | 506,633 |
Peter Zorn |
313 | 4,479 |
Merouane Bencherif |
155,242 | 0 |
Mauri Hodges |
0 | 0 |
Karen Hicks |
0 | 0 |
David Hosford |
0 | 0 |
Charles Blixt |
0 | 0 |
Julia Brown |
0 | 0 |
Errol De Souza |
0 | 0 |
Alan Dunton |
0 | 0 |
John Richard |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
SANDELL SCOTT D |
1,000 | $0.08 |
BARRETT MICHAEL JAMES |
1,000 | $0.08 |
BARRIS PETER J |
1,000 | $0.08 |
BROWN JULIA R |
6,000 | $5.09 |
HILL STEPHEN A |
10,000 | $4.38 |
HILL STEPHEN A |
10,000 | $4.48 |
KRAMLICH C RICHARD |
3,333 | $0.08 |
SANDELL SCOTT D |
3,333 | $0.08 |
BARRIS PETER J |
3,333 | $0.08 |
BVF PARTNERS L P |
217,000 | $4.00 |
BVF PARTNERS L P |
378,000 | $4.00 |
BVF PARTNERS L P |
444,649 | $4.00 |
BVF PARTNERS L P |
772,063 | $4.00 |
BVF PARTNERS L P |
17,400 | $4.01 |
BVF PARTNERS L P |
31,929 | $4.01 |
BVF PARTNERS L P |
14,300 | $4.08 |
BVF PARTNERS L P |
8,800 | $4.08 |
BVF PARTNERS L P |
36,100 | $4.05 |
BVF PARTNERS L P |
21,500 | $4.05 |
BVF PARTNERS L P |
6,700 | $4.05 |
BVF PARTNERS L P |
23,400 | $4.05 |
BVF PARTNERS L P |
46,700 | $4.06 |
BVF PARTNERS L P |
5,300 | $4.06 |
BURRILL GEORGE STEVEN |
4,333 | $0.08 |
RICHARD JOHN P |
7,500 | $4.16 |

